> 首页 > 产品 > 一抗 > 其他 > Anti-CLDN18.2 Reference Antibody (osemitamab)

Anti-CLDN18.2 Reference Antibody (osemitamab)

Anti-CLDN18.2 Reference Antibody (osemitamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-CLDN18.2 Reference Antibody (osemitamab) is 99.4%, determined by SEC-HPLC.
Human 18.2-HEK293 cells at 1E5 cell/well were stained with osemitamab and negative control protein respectively, washed and then followed by PE and analyzed with FACS, with the EC50 is 2.134 nM.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P56856
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	27856 Da

Additional Information
Target/Specificity	CLDN18.2
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	CLDN18
Function	Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription (By similarity). Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency (By similarity). Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways (By similarity).
Cellular Location	Cell junction, tight junction {ECO:0000250\|UniProtKB:P56857}. Cell membrane {ECO:0000250\|UniProtKB:P56857}; Multi-pass membrane protein. Note=Localizes to tight junctions in epithelial cells {ECO:0000250\|UniProtKB:P56857} [Isoform A2]: Cell junction, tight junction {ECO:0000250\|UniProtKB:P56857}. Lateral cell membrane {ECO:0000250\|UniProtKB:P56857}
Tissue Location	[Isoform A1]: Expression is restricted to the lung.

Research Areas

Application Protocols

Provided below are standard protocols that you may find useful for product applications.

Western Blot Protocol

Blocking Peptides Protocol

Dot Blot Protocol

Immunohistochemistry Protocol

Immunofluorescence Protocol

Immunoprecipitation Protocol

Flow Cytomety Protocol

Cell Culture Protocol